Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Primary testicular (PT) diffuse large B-cell lymphoma (DLBCL) is a rare and aggressive lymphoma with distinct clinical and molecular characteristics. To identify prognostic biomarkers in PT-DLBCL, in this study we analyzed DNA and RNA samples of PT-DLBCL tumors from 206 patients using next-generation sequencing platforms and assays. Genetic alteration analysis found that multiple chromosomal copy number variations (CNVs), TP53 transcript mutations with high variant allele frequency, and MCD subtype had significantly adverse prognostic effects, whereas elevated microsatellite instability had a significantly favorable prognostic effect in PT-DLBCL. Targeted RNA-seq analysis identified a PTL gene expression signature by comparing PT-DLBCL with systemic DLBCL and revealed the heterogeneity within PT-DLBCL by unsupervised clustering, which classified PT-DLBCLs into a testicular lymphoma tumor (TLT) subtype and a microenvironment (ME) subtype. The TLT subtype featured upregulation of genes functioning in DNA damage response, DNA repair, chromatin remodeling, the cell cycle, and the nucleus, and was associated with significantly poorer patient survival and higher frequencies of MYD88 mutations, multiple CNVs, MCD subtype, bulk tumors, and elderly patients in the PT-DLBCL cohort. In contrast, the ME subtype distinctively featured upregulation of various signaling pathway genes involving the tumor microenvironment and downregulation of BTK and B-cell receptor signaling genes, and was associated with significantly better clinical outcome than the TLT subtype of PT-DLBCL independently of CNVs, MCD and MYD88 mutation and than systemic DLBCL. Moreover, genomic microRNA profiling analysis identified a PTL microRNA signature significantly differentially expressed between PT-DLBCL and systemic DLBCL patients and within the PT-DLBCL cohort, and PT-DLBCL patients with higher expression of 16 PTL microRNAs (14 are testicular tissue-specific) had significantly better survival. In summary, this study revealed the molecular heterogeneity in genetic abnormalities and expression profiles of coding genes and microRNAs within the PT-DLBCL entity, and identified significant prognostic biomarkers and PTL signatures.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12271531PMC
http://dx.doi.org/10.1038/s41408-025-01323-8DOI Listing

Publication Analysis

Top Keywords

systemic dlbcl
12
tlt subtype
12
pt-dlbcl
11
gene expression
8
microrna profiling
8
primary testicular
8
testicular diffuse
8
diffuse large
8
large b-cell
8
b-cell lymphoma
8

Similar Publications

Background: The coexistence of neuropsychiatric systemic lupus erythematosus (NPSLE) and primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS) (PCNS DLBCL) is extremely rare in clinical practice. This article retrospectively analyzes the clinical manifestations, imaging examinations, pathological diagnosis, and treatment process of a patient with NPSLE, from the appearance of intracranial abnormal signal shadows to the final diagnosis of PCNS DLBCL.

Case Summary: A 32-year-old Chinese female patient had previously visited our hospital due to vomiting and delirium and was diagnosed with NPSLE.

View Article and Find Full Text PDF

Background: In the absence of a head-to-head trial of off-the-shelf subcutaneous epcoritamab, a novel CD3xCD20 bispecific antibody, versus chimeric antigen receptor T-cell therapy (CAR T), a matching-adjusted indirect comparison (MAIC) of epcoritamab versus axicabtagene ciloleucel (axi-cel) efficacy was conducted in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with ≥ 2 prior lines of systemic therapy.

Methods: The MAIC used epcoritamab patient-level data from EPCORE NHL-1 (NCT03625037; April 2023 data cutoff) and axi-cel aggregated data from ZUMA-1 (NCT02348216). Patients without prior CAR T were matched to the ZUMA-1 population; weighted regression models were used to estimate absolute differences in overall response rate (ORR) and complete response (CR) rate, and weighted Cox proportional-hazards models were used to estimate hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS).

View Article and Find Full Text PDF

: Metabolic tumor volume (MTV) and inflammation-based indices have recently gained attention as potential prognostic markers of diffuse large B-cell lymphoma (DLBCL). We aimed to evaluate the prognostic significance of metabolic and systemic inflammatory parameters in predicting treatment response, relapse, and overall survival (OS) in patients with DLBCL. : This retrospective cohort study included 70 patients with DLBCL.

View Article and Find Full Text PDF

Treatment of Diffuse Large B-cell Lymphoma Progressing or Relapsing after Chimeric Antigen Receptor T-cell Therapy.

Transplant Cell Ther

August 2025

Research Methodology and Biostatistics Core, Office of Research Morsani College of Medicine, University of South Florida, Tampa, Florida. Electronic address:

There is no established standard treatment for diffuse large B-cell lymphoma (DLBCL) progressing or relapsing after chimeric antigen receptor T-cell therapy (CAR T-cell). While enrollment in clinical trials is ideal, unfortunately, many are not eligible to participate. Various treatment modalities exist with heterogeneous efficacies.

View Article and Find Full Text PDF

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, characterized by high heterogeneity and significant clinical challenges. Despite the widespread adoption of the R-CHOP regimen as the standard treatment, approximately 30 %-40 % of patients experience relapse, necessitating the development of novel therapeutic strategies. Here, we presented a multifunctional therapeutic platform combining oncolytic vaccinia virus (OVV) and the second near-infrared (NIR-II) fluorescent dye IR1061, encapsulated within Sophora flavescens-derived extracellular vesicles (SFNPs), termed SFOVV@IR1061.

View Article and Find Full Text PDF